Over 100 million doses of Russia’s Sputnik vaccine will be produced in China per year, the Russian Direct Investment Fund (RDIF) announced Monday.
RDIF, which co-developed Sputnik V, said it has partnered with China’s Hualan Biological Bacterin Inc. to produce doses of Russia’s vaccines.
Hualan Biological Bacterin Inc. is a subsidiary of China’s largest influenza vaccine manufacturer, Hualan Biolgoical Engineering Inc.
“This amount of the vaccine will be sufficient to vaccinate over 50 million people. RDIF and Hualan Biological Bacterin are committed to the long-term partnership in terms of the vaccine production,” RDIF said in a press release.
RDIF Chief Executive Officer Kirill Dmitriev, for his part, said the partnership with China will help “significantly increase the production capacities of Sputnik V.”
“China is one of the key partners in production of the Russian vaccine, which is already used virtually in every part of the world to protect people’s health as Sputnik V has proved to be safe and highly effective,” Dmitriev added.
Sputnik V has been registered in over 60 countries.
Based on data from medical journal The Lancet, the Russian vaccine has an efficacy of 91.6 percent.